Imagine Media Ltd. (IMLE) shares skyrocket after buying anti-DUI tech company

Posted on: April 27th, 2011
Written by:
admin

Imagine Media Ltd. (OTCBB: IMLE), a Delaware corporation, climbed 35 cents, or 140%, Wednesday morning to 60 cents, after announcing that it has signed a non-binding Letter of Intent (“LOI”) to acquire TransBioTec Corporation. Volume for the stock was 86,000 shares by noon ET.

TransBioTec, with headquarters in Seal Beach, California, has developed and patented, a high technology, state-of-the-art transdermal sensor, that detects blood alcohol levels through a person’s skin. Ethanol is produced as alcohol is ingested and metabolized in the body. The system senses ethanol excreted through a person’s sweat.

A person places their finger on the sensor, and within five to eight seconds, the sensor will detect the ethanol level. A signal can then be sent to output devices that control the ignition in a vehicle to prevent it from starting.

The TransBioTec system touted as unobtrusive, accurate, reliable, durable, low-cost, easier to use, and faster than the current breathalyzer applications.

Imagine President Greg Bloom, commented, “We are extremely excited about the possibility of acquiring TBT, and bringing its significant opportunities to our shareholders, as well as helping to introduce this innovative technology that will save countless lives.”

Charles Bennington, Cheif Executive Officer of TBT also commented, “We are truly excited to be able to deliver a first-to-market technology that many companies have been attempting to design to address the growing drunk driving issues that claim so many lives and cause so much property damage every year.”

no comments

Advaxis Inc. (ADXS) gains more than 6% after presentation

Posted on: April 18th, 2011
Written by:
Glenn

Advaxis Inc. (OTCBB: ADXS) enjoyed a healthy gain of 6.3% Monday afternoon, after one of its chief scientists gave a presentation at a prestigious conference. The New Jersey-based vaccine company gained a penny in late Monday trading to 16.9 cents, still far short of its 52-week high of 25 cents posted last May, on volume of nearly 600,000 shares.

Over the weekend, Advaxis Executive Vice President of Science and Operations Dr. John Rothman, spoke about “The Use of Live Attenuated Listeria that Express LLO-Antigen Fusion Proteins for the Treatment of Cancer” in a Target Meeting webinar entitled “Immunotherapy: a promising way for cancer treatment.”

In his presentation, he reported that Advaxis has treated 72 patients with 180 doses of live attenuated Listeria safely, to-date; that drug-related side effects have been infrequent and are typically mild to moderate when they occur. Rothman also noted that, when side effects have occurred, they have been treated symptomatically and have not required antibiotics – indicating that the side effects are not related to the onset of Listerial disease but result from strong innate immune stimulation which causes a flu-like syndrome of fever and chills and occasionally nausea.

“What we witnessed in the clinic confirms the data in the laboratory,” Dr. Rothman told the scientific audience. “We have developed strains of Listeria that can be given to mice in doses 100,000 times greater than the normally lethal levels of the wild type bacterium without any animals dying. Our experience with end-stage cancer patients using our attenuated Listeria indicates that they can be given safely even to those who have very weakened immune systems.”

Based in North Brunswick, New Jersey, Advaxis is a biotechnology company developing proprietary, live but attenuated, Listeria monocytogenes (Listeria) vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to fight cancer. Advaxus’ platform technology was developed by Dr. Yvonne Paterson at The University of Pennsylvania. Today, the Company has over nine distinct, cancer-fighting constructs in various stages of development.

no comments

Cord Blood America (CBAI) volume skyrockets on acquisition news

Posted on: September 20th, 2010
Written by:
Sheryl

Cord Blood America, Inc. (OTCBB: CBAI) experienced explosive activity Monday, trading nearly 40 million shares after announcing this morning that the Company has acquired a 50.1 percent controlling interest in Biocordcell Argentina S.A. (BioCells, Inc.), one of South America’s largest stem cell companies. Cord  Blood America primarily focuses on the preservation of umbilical cord blood stem cell  in order to bring the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally.

Commanding a major part of the market in South America, BioCells is headquartered in Argentina with operations in Peru, Colombia, Bolivia, Panama and Puerto Rico, with recent expansion into Uruguay and Paraguay.  Purchase price for the profitable stem cell storage company, the second largest in Argentina, depends on achieving earn out targets for net profit over the next two years.

BioCells, Inc. reported 2009 annual revenues of $1.2 million (US), and operates twelve locations throughout Argentina, serving the nation of 40 million people that historically saves umbilical cord blood stem cells at a rate even higher than in the United States.

Co-founder and Chief Executive Officer of Cord Blood America, Matthew Schissler commented, “We expect revenues from BioCells to be approximately $1.7 million in 2010, with a profit of $150,000 (U.S.) before taxes. With this acquisition in South America, we now own a state-of-the-art large laboratory in Las Vegas, Nevada, a stem cell company in Germany with expansion plans throughout Europe, and we are partners in what could be the world’s largest stem cell storage facility in China.  We are quite proud of the accomplishments of Cord Blood America and we have no intention of slowing our aggressive growth strategy.”

Schissler concluded, “This is an historic day for Cord Blood America, our loyal investors and stakeholders.  We will not rest until we meet our goal of becoming the world’s premier stem cell storage company.”

no comments

Applied DNA Sciences, Inc. (APDN) signs contract with Safe Solution AB

Posted on: February 18th, 2010
Written by:
Sheryl

Applied DNA Sciences, Inc. (OTCBB: APDN), provider of DNA-based security solutions, today announced that the Company has entered a three-year contract with Sweden-based Safe Solutions AB, to market and sell SigNature DNA Forensic products and services to the Scandinavian market. This news marks yet another milestone for Applied DNA, which has enjoyed a 33 percent increase in share prices since the start of the new calendar year.

Leif Svensson, Chief Executive Office of Safe Solution AB, brings years of experience of cash-in-transit security, as former CEO of G4S Cash Services and as former Chief Security Officer at Swedish airports Arlanda and Bromma.

Commenting on the collaboration, Svensson stated, “Applied DNA Sciences has developed a fantastic concept, based on its unique botanical SigNature DNA, which will definitely hamper and prevent serious crime. Initially we are launching SigNature DNA in the cash and banking sectors but this is a security solution with large and multiple uses, such as for domestic protection, cargo protection and storage, which are important national concerns in Sweden”.

Safe Solution plans to introduce SigNature DNA products immediately in Sweden, while promoting Applied DNA’s technology, consisting of its unique botanical DNA taggant combined with its proprietary cash degradation dye, AzSure™. With the same technology, Safe Solution is planning to launch enterprise security and home protection products for end-consumers.

In recent years, Sweden has experienced increasingly frequent and violent crimes, and statistics from the European Security Transport Association (ESTA) show that Sweden ranks third with regard to the number of cash transport robberies in relation to population. Furthermore, Sweden accounts for one tenth of the total capital losses in cash transport robberies in Europe.

Applied DNA Sciences CEO, Dr. James Hayward believes this strategic partnership will provide a significant deterrent to such crimes, stating, “SigNature DNA has already proven its value in other European cash-in-transit markets where it has been used to assist the police in catching and prosecuting criminals, securing longer sentences than might otherwise have been possible.”

Hayward continued, “With this significant partnership and working in close collaboration with the National Police, we will be able to contribute to reducing cash-in-transit crimes and protecting the Scandinavian public from illicit crimes.”

no comments

Kraig Biocraft (KBLB) plans to double genetic insertions

Posted on: May 27th, 2009
Written by:
Sheryl

Kraig Biocraft Laboratories, Inc. (OTCBB: KBLB) skyrocketed 861 percent to 25 cents per share, from Tuesday’s closing price of two-and-a-half cents per share, after the company announced it is gearing up to double the number of genetic insertions performed. The company specializes in the commercialization of new textiles and high performance fibers, and is working to develop high performance polymers using spider silk gene sequences.

Earlier this month, Kraig announced that its scientific team had recently succeeded in building eight unique DNA constructs, specifically targeted for the production of new fusion silk proteins, which the team is preparing for genetic insertion over the next few weeks. Kraig anticipates that the rate of DNA construct insertions in May will be double that which has been performed to date.

CEO Kim Thompson commented on this breakthrough, “We are now entering the next phase in which the team is reallocating recourses to genetic insertion. This is directly related to our recent development of new DNA constructs that are specifically targeted for the production of new fusion silk proteins. We intend to dramatically ramp up the number of insertions performed in order to gain the maximum benefit from the new insertion packets.”

The goal of these genetic insertions is the mass production of spider silk, known for its incredible tensile strength, and stronger than steel by weight. Kraig hopes to tap into, and dominate the $92 billion high performance fiber industry.

In 2007 Kraig Biocraft Laboratories signed an intellectual property and collaborative research agreement with the University of Notre Dame. Since that time the Company has been a proud sponsor of scientific research and development within the university.

no comments

EcoSystem Corporation (ESYM) announces new technology

Posted on: March 18th, 2009
Written by:
Sheryl

EcoSystem Corp (OTCBB: ESYM) shares jumped six percent over Tuesday’s closing price after the company announced new technology to be implemented in converting food scrap waste into natural oils for biodiesel feedstock and various specialty chemical applications.

The company introduced MAGFUEL biofuel feedstock model, which employs the use of the Black Soldier Fly to convert food scrap waste. EcoSystem predicts its conversion technology could yield up to 190,000 gallons of crude natural oils per acre of bioreactor surface annually, which far surpasses the 40 gallons of oil per acre annually yielded by soybeans.

At the core of EcoSystem’s bioreactor technology is the use of the Black Soldier Fly, a insect commonly used compost and manure management. The company estimates estimates that 25% of the volume of retail, restaurant, and industrial generated food waste could be converted into Black Soldier Fly larvae. Based upon U.S. 2010 Census data, up to 100 million gallons per year of MAGFUEL(TM) natural oils could be produced and sold to U.S. biodiesel producers using EcoSystem technology.

Glen Courtright, President and CEO of EcoSystem commented “Competitively-priced feedstock has always been a challenge for the biodiesel industry. We are excited to develop this competitively priced, high quality feedstock to the biodiesel industry by diverting food scrap waste from landfills. We are in discussions now with a number of very interested early-adopter partners for co-location of our bioreactor technology.”

EcoSystem plans to market the MAGFUEL into the existing biodiesel industry as a blending agent for lower grade biodiesel feedstocks. The company’s revenue model will be comprised of tipping fees associated with the transfer and processing of scrape waste materials, as well as MAGFUEL and other product sales.

no comments


About Penny Stocks

The term "penny stocks," also known as micro-cap equities, micro caps, small caps, pink sheets, refers to shares in a company that trades for less than $5.00. Most penny stocks trade on the OTCBB market and the pink sheet electronic quotation service. Penny Stocks can be very volatile and can see gains as much as 500% in a day. Volatility in penny stocks is also dangerous because penny stocks can come down as quickly as they go up. If you trade penny stocks based on stock picks, make sure to always do your due diligence on the companies you're considering, use stop loss orders, and book your profits when you are in a position to do so.